Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

183 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features.
Kumar S, Dispenzieri A, Katzmann JA, Larson DR, Colby CL, Lacy MQ, Hayman SR, Buadi FK, Leung N, Zeldenrust SR, Ramirez-Alvarado M, Clark RJ, Kyle RA, Rajkumar SV, Gertz MA. Kumar S, et al. Among authors: zeldenrust sr. Blood. 2010 Dec 9;116(24):5126-9. doi: 10.1182/blood-2010-06-290668. Epub 2010 Aug 26. Blood. 2010. PMID: 20798235 Free PMC article.
Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs.
Dispenzieri A, Dingli D, Kumar SK, Rajkumar SV, Lacy MQ, Hayman S, Buadi F, Zeldenrust S, Leung N, Detweiler-Short K, Lust JA, Russell SJ, Kyle RA, Gertz MA. Dispenzieri A, et al. Am J Hematol. 2010 Oct;85(10):757-9. doi: 10.1002/ajh.21822. Am J Hematol. 2010. PMID: 20872958 Free PMC article.
Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein.
Tschautscher M, Rajkumar V, Dispenzieri A, Lacy M, Gertz M, Buadi F, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman S, Zeldenrust S, Lust J, Russell S, Leung N, Kapoor P, Go R, Lin Y, Gonsalves W, Kourelis T, Warsame R, Kyle R, Kumar S. Tschautscher M, et al. Am J Hematol. 2018 Oct;93(10):1207-1210. doi: 10.1002/ajh.25215. Epub 2018 Aug 15. Am J Hematol. 2018. PMID: 30016549 Free article.
Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.
Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Gertz MA. Kumar S, et al. Among authors: zeldenrust sr. J Clin Oncol. 2012 Mar 20;30(9):989-95. doi: 10.1200/JCO.2011.38.5724. Epub 2012 Feb 13. J Clin Oncol. 2012. PMID: 22331953 Free PMC article.
Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosis.
Hwa YL, Warsame R, Gertz MA, Buadi FK, Lacy MQ, Kumar SK, Dingli D, Zeldenrust SR, Leung N, Hayman SR, Kapoor P, Gonsalves WI, Kourelis TV, Russell S, Go RS, Hobbs MA, Fonder AL, Rajkumar SV, Dispenzieri A. Hwa YL, et al. Among authors: zeldenrust sr. Blood. 2017 Sep 28;130(13):1578-1584. doi: 10.1182/blood-2017-05-783415. Epub 2017 Aug 14. Blood. 2017. PMID: 28807981 Free article.
Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis.
Hwa YL, Gertz MA, Kumar SK, Lacy MQ, Buadi FK, Dingli D, Kapoor P, Zeldenrust SR, Leung N, Hayman SR, Gonsalves WI, Kourelis TV, Warsame R, Go RS, Muchtar E, Hobbs MA, Fonder AL, Russell S, Kyle RA, Rajkumar SV, Dispenzieri A. Hwa YL, et al. Among authors: zeldenrust sr. Leukemia. 2019 May;33(5):1268-1272. doi: 10.1038/s41375-019-0400-5. Epub 2019 Feb 8. Leukemia. 2019. PMID: 30737485
Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis.
Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Zeldenrust S, Kumar S, Hayman S, Buadi F, Kyle RA, Greipp PR, Lust JA, Russell S, Rajkumar SV, Fonseca R, Dispenzieri A. Bryce AH, et al. Haematologica. 2009 Mar;94(3):380-6. doi: 10.3324/haematol.13369. Epub 2009 Feb 11. Haematologica. 2009. PMID: 19211640 Free PMC article.
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma.
Madan S, Lacy MQ, Dispenzieri A, Gertz MA, Buadi F, Hayman SR, Detweiler-Short K, Dingli D, Zeldenrust S, Lust J, Greipp PR, Rajkumar SV, Kumar S. Madan S, et al. Among authors: zeldenrust s. Blood. 2011 Aug 18;118(7):1763-5. doi: 10.1182/blood-2011-04-350009. Epub 2011 Jun 14. Blood. 2011. PMID: 21673347 Free PMC article.
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.
Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Stewart AK, Laumann K, Mandrekar SJ, Reeder C, Rajkumar SV, Mikhael JR. Lacy MQ, et al. Among authors: zeldenrust s. Blood. 2011 Sep 15;118(11):2970-5. doi: 10.1182/blood-2011-04-348896. Epub 2011 Jun 20. Blood. 2011. PMID: 21690557 Free PMC article. Clinical Trial.
183 results